Reversibility of FUS-aided blood–tumor barrier opening for the delivery of therapeutics
In a dual-GBM mouse model, FUS was applied to selectively open the blood–tumor barrier in one tumor to assess 18 F-avelumab and 18 F-FDS penetration over 1–72 h, addressing whether FUS-induced barrier disruption is reversible.
Authors
- Erwan Selingue (ORCID: https://orcid.org/0000-0002-8364-8659)
- Céline Chevaleyre
- Benoît Larrat (ORCID: https://orcid.org/0000-0003-1577-6293)
- Anthony Novell (ORCID: https://orcid.org/0000-0003-3649-0956)
- Sébastien Mériaux (ORCID: https://orcid.org/0000-0001-7430-8348)
- Sébastien Tran (ORCID: https://orcid.org/0000-0001-6619-2795)
- Nicolas Tournier (ORCID: https://orcid.org/0000-0002-0755-2030)
- Laurène Jourdain
- Charles Truillet (ORCID: https://orcid.org/0000-0002-1782-5418)
- Mylène Richard (ORCID: https://orcid.org/0000-0003-0305-578X)
- Dimitri Kereselidze
- Benoit Jégo
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Université Paris-Saclay (FR)
- CEA Paris-Saclay - Etablissement de Saclay (FR)
- Institut d'Imagerie Biomédicale (FR)
- CEA Paris-Saclay (FR)
Publication Details
- Journal
- RSC Pharmaceutics
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1039/d5pm00088b
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Agence Nationale de la Recherche
- Institut National de la Santé et de la Recherche Médicale